Belgium: Galapagos accelerates access to next-generation cell therapies with CellPoint and AboundBio acquisitions

Paul Stoffels, MD and CEO of Galapagos

Mechelen-based Galapagos, a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines, is acquiring CellPoint and AboundBio, propelling Galapagos into next-generation cell therapy while broadening its portfolio and capabilities. Through the acquisition of CellPoint and AboundBio, respectively, Galapagos gains access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model…

You must be a HMI Subscriber to view this content.

Subscribe Now »